Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

Core Insights - Milestone Pharmaceuticals has appointed David Sandoval as General Counsel and Chief Compliance Officer, coinciding with the launch of CARDAMYST™ (etripamil) nasal spray, the first self-administered treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults [1][3] Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines, with CARDAMYST™ as its lead product [16] - CARDAMYST™ is a novel calcium channel blocker nasal spray approved by the FDA for converting acute symptomatic episodes of PSVT to sinus rhythm in adults [5][16] Product Details - CARDAMYST™ is designed as a self-administered rapid response therapy, allowing patients to manage their condition without immediate medical oversight [5] - The product has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT treatment [6] Leadership Appointment - David Sandoval brings over 15 years of experience in legal and compliance functions within the life sciences sector, focusing on late-stage development and regulatory approval [2] - His previous roles include Senior Vice President and General Counsel at MaxCyte, where he oversaw global legal and compliance activities and played a key role in strategic transactions [2][4] Strategic Importance - The appointment of Mr. Sandoval is seen as critical for Milestone as it prepares for the commercialization of CARDAMYST, with expectations of scaling operations and building infrastructure for long-term growth [3]